---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-24-000018"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2024-07-25T23:59:59+00:00"
generated_at: "2026-05-31T16:18:39.086390+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NovoCure Q2 revenue $150M (+19% YoY), net loss $33.4M, METIS trial positive

## Summary
- Net revenues $150.4M, up 19% YoY; U.S. contributed $95.7M, Germany $15.1M, France $14.3M.
- Net loss $33.4M ($0.31 per share); adjusted EBITDA $1.1M; cash and investments $951.2M.
- Phase 3 METIS trial in brain metastases from NSCLC met primary endpoint; presented at ASCO 2024.
- Active patients 3,963 as of June 30, 2024; prescriptions 1,634, up 5% YoY.
- Gross margin 77%; research & development expenses $55.0M; sales & marketing $56.6M.

## SEC filing metadata
- accession: 0001645113-24-000018
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2024-07-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000018/0001645113-24-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000018/nvcr-20240725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-24-000018
- JSON: https://secwatch.observer/filing/0001645113-24-000018.json
- Plain text: https://secwatch.observer/filing/0001645113-24-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.